Gross tumor volume delineation in primary prostate cancer on 18F-PSMA-1007 PET/MRI and 68Ga-PSMA-11 PET/MRI

被引:8
|
作者
Zhang, Yan-Nan [1 ]
Lu, Zhen-Guo [1 ]
Wang, Shuai-Dong [2 ]
Lu, Xin [1 ]
Zhu, Lei-Lei [1 ]
Yang, Xu [1 ]
Fu, Li-Ping [1 ]
Zhao, Jun [3 ]
Wang, Hai-Feng [2 ]
Xiang, Zuo-Lin [1 ]
机构
[1] Tongji Univ, Sch Med, Shanghai East Hosp, Dept Radiat Oncol, Shanghai 200120, Peoples R China
[2] Tongji Univ, Sch Med, Shanghai East Hosp, Dept Urol, Shanghai 200120, Peoples R China
[3] Tongji Univ, Sch Med, Shanghai East Hosp, Dept Nucl Med, Shanghai 200120, Peoples R China
基金
中国国家自然科学基金;
关键词
Prostate cancer; Gross tumor volume; Radiotherapy; PSMA PET; MRI; HYBRID PET/MRI; PET/CT; VALIDATION; PSMA; MRI; RECURRENCE; GUIDELINES; LESIONS;
D O I
10.1186/s40644-022-00475-1
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background We aimed to assess the clinical value of F-18-PSMA-1007 and Ga-68-PSMA-11 PET/MRI in the gross tumor volume (GTV) delineation of radiotherapy for prostate cancer (PCa). Methods Sixty-nine patients were retrospectively enrolled (57 in the F-18 subgroup and 12 in the Ga-68 subgroup). Three physicians delineated the GTV and tumor length by the visual method and threshold method with thresholds of 30%, 40%, 50%, and 60% SUVmax. The volume correlation and differences in GTVs were assessed. The dice similarity coefficient (DSC) was applied to estimate the spatial overlap between GTVs. For 51 patients undergoing radical prostatectomy, the tumor length (Lpath) of the maximum area was measured, and compared with the longest tumor length obtained based on the images (L-MRI, L-PET/MRI, L-PET, L-PET30%, L-PET40%, L-PET50%, L-PET60%) to determine the best delineation method. Results In the F-18 subgroup, (1) GTV-PET/MRI (p < 0.001) was significantly different from the reference GTV-MRI. DSC between them was > 0.7. (2) GTV-MRI (R-2 = 0.462, p < 0.05) was the influencing factor of DSC. In the Ga-68 subgroup, (1) GTV-PET/MRI (p < 0.05) was significantly different from the reference GTV-MRI. DSC between them was > 0.7. (2) There was a significant correlation between GTV-MRI (r = 0.580, p < 0.05) and DSC. The longest tumor length measured by PET/MRI was in good agreement with that measured by histopathological analysis in both subgroups. Conclusion It is feasible to visually delineate GTV on PSMA PET/MRI in PCa radiotherapy, and we emphasize the utility of PET/MRI fusion images in GTV delineation. In addition, the overlap degree was the highest between GTV-MRI and GTV-PET/MRI, and it increased with increasing volume.
引用
收藏
页数:11
相关论文
共 50 条
  • [21] Diagnostic value of integrated 18F-PSMA-1007 PET/MRI compared with that of biparametric MRI for the detection of prostate cancer
    Zeng, Yuping
    Leng, Xiaoming
    Liao, Hengbin
    Jiang, Guihua
    Chen, Ping
    PROSTATE INTERNATIONAL, 2022, 10 (02) : 108 - 116
  • [22] 68Ga-PSMA-11 PET/CT versus 68Ga-PSMA-11 PET/MRI for the detection of biochemically recurrent prostate cancer: a systematic review and meta-analysis
    Huang, Ruizhe
    Li, Yizhen
    Wu, Haowen
    Liu, Boyi
    Zhang, Xuanjun
    Zhang, Zhongxi
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [23] PSMA-ligand PET/CT in patients with biochemical recurrent prostate cancer after radical prostatectomy: matched-pair comparison of 68Ga-PSMA-11 and 18F-PSMA-1007
    Kroenke, Markus
    Rauscher, Isabel
    Horn, Thomas
    Weber, Wolfgang
    Eiber, Matthias
    JOURNAL OF NUCLEAR MEDICINE, 2019, 60
  • [24] Head-to-Head Comparison of 68Ga-PSMA-11 with 18F-PSMA-1007 PET/CT in Staging Prostate Cancer Using Histopathology and Immunohistochemical Analysis as a Reference Standard
    Kuten, Jonathan
    Fahoum, Ibrahim
    Savin, Ziv
    Shamni, Ofer
    Gitstein, Gilad
    Hershkovitz, Dov
    Mabjeesh, Nicola J.
    Yossepowitch, Ofer
    Mishani, Eyal
    Even-Sapir, Einat
    JOURNAL OF NUCLEAR MEDICINE, 2020, 61 (04) : 527 - 532
  • [25] Pilot trial comparing the performance of 68Ga-PSMA-11 PET/CT to 18F-PSMA-1007 PET/CT in the detection of prostate cancer recurrence in men with rising PSA following radical prostatectomy
    Sheehan-Dare, Gemma
    Ende, Jesse
    Amin, Amer
    Cusick, Thomas
    Ho, Bao
    Keane, Joanne
    Nguyen, Andrew
    Liu, Victor
    Lee, Jonathan
    Chen, Andrew
    Chan, Lyn
    Fullard, Karen
    Stricker, Phillip
    Emmett, Louise
    JOURNAL OF NUCLEAR MEDICINE, 2021, 62
  • [26] Assessment of benign bone marrow uptake with 18F-PSMA-1007 in prostate cancer using PET/MRI
    Afaq, Asim
    Wan, Ming Young Simon
    Priftakis, Dimitrios
    Kayani, Irfan
    Bomanji, Jamshed
    JOURNAL OF NUCLEAR MEDICINE, 2020, 61
  • [27] MRI versus 68Ga-PSMA PET/CT for gross tumour volume delineation in radiation treatment planning of primary prostate cancer
    Constantinos Zamboglou
    Gesche Wieser
    Steffen Hennies
    Irene Rempel
    Simon Kirste
    Martin Soschynski
    Hans Christian Rischke
    Tobias Fechter
    Cordula A. Jilg
    Mathias Langer
    Philipp T. Meyer
    Michael Bock
    Anca-Ligia Grosu
    European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43 : 889 - 897
  • [28] MRI versus 68Ga-PSMA PET/CT for gross tumour volume delineation in radiation treatment planning of primary prostate cancer
    Zamboglou, Constantinos
    Wieser, Gesche
    Hennies, Steffen
    Rempel, Irene
    Kirste, Simon
    Soschynski, Martin
    Rischke, Hans Christian
    Fechter, Tobias
    Jilg, Cordula A.
    Langer, Mathias
    Meyer, Philipp T.
    Bock, Michael
    Grosu, Anca-Ligia
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2016, 43 (05) : 889 - 897
  • [29] Pilot trial comparing the performance of 68Ga-PSMA-11 PET/CT to 18F-PSMA-1007 PET/CT in the detection of prostate cancer recurrence in men with rising PSA following radical prostatectomy
    Amin, Amer
    Ende, Jesse
    Stricker, Phillip
    Emmett, Louise
    INTERNATIONAL JOURNAL OF UROLOGY, 2020, 27 : 112 - 112
  • [30] Feasibility of Different Tumor Delineation Approaches for 18F-PSMA-1007 PET/CT Imaging in Prostate Cancer Patients
    Mittlmeier, Lena M.
    Brendel, Matthias
    Beyer, Leonie
    Albert, Nathalie L.
    Todica, Andrei
    Zacherl, Mathias J.
    Wenter, Vera
    Herlemann, Annika
    Kretschmer, Alexander
    Ledderose, Stephan T.
    Schmidt-Hegemann, Nina-Sophie
    Kunz, Wolfgang G.
    Ricke, Jens
    Bartenstein, Peter
    Ilhan, Harun
    Unterrainer, Marcus
    FRONTIERS IN ONCOLOGY, 2021, 11